

A Mutation Causing Reduced Biological Activity and Stability of Thyroxine-Binding Globulin Probably as a Result of Abnormal Glycosylation of the Molecule

Yuichi Mori, Susumu Seino, Kyoko Takeda, Irwin L. Flink*, Yoshiharu Murata†, Graeme I. Bell, and Samuel Refetoff

Department of Medicine (Y.M., K.T., G.I.B., S.R.)
Department of Pediatrics (S.R.)
Department of Biochemistry and Molecular Biology and Howard Hughes Medical Institute (S.S., G.I.B.)
The University of Chicago
Chicago, Illinois 60637

T₄-binding globulin (TBG), a 54-kilodalton glycoprotein, is the major thyroid hormone transport protein in man. The exact nature of the mutations causing X chromosome-linked TBG deficiency, which affect about 1 in 2,500 newborn males, is unknown. Here we report the sequence of a unique variant TBG (TBG-Gary) encoding a protein with severely impaired T₄ binding as well as decreased stability at 37 C, resulting in its rapid *in vivo* denaturation. A single nucleotide substitution in the codon for residue 96 of the mature protein replaces isoleucine with asparagine; this replacement creates an additional site for N-linked glycosylation. The anodal shift of TBG-Gary on isoelectric focusing gel electrophoresis suggests that this new site is likely glycosylated. Since glycosylation is required for TBG to assume its correct tertiary structure, but is not subsequently necessary for maintenance of the biological properties or stability of the molecule, we believe that the likely presence of additional carbohydrate probably affects a higher order structure of the molecule and is thus responsible for the reduced stability and hormone binding activity of TBG-Gary (TBG^{ASN-96}) (Molecular Endocrinology 3: 575-579, 1989)

INTRODUCTION

T₄-binding globulin (TBG), is a 54 kilodalton serum glycoprotein composed of a single polypeptide chain and four carbohydrate residues (1, 2). It is synthesized by the liver (3, 4), and its principal function is to bind

thyroid hormone and thus, increase its intravascular pool (2). Changes in TBG concentration produce proportional alterations in the level of T₄ in serum (5-8). However, because the hormone is transported into cells in a free rather than TBG-bound form, TBG abnormalities have no effect on the metabolic state, general health, or survival of the individual (1, 2, 5-8). Nevertheless, inappropriate therapeutic interventions to correct the alterations of thyroid hormone concentration in the serum of such individuals are not uncommon, and in fact, can be detrimental (8, 9) This is particularly relevant as inherited abnormalities of TBG are relatively common, affecting about 1 of 2,500 newborn males (10, 11). Inherited TBG defects are X chromosome linked and expressed in hemizygotes as complete or partial TBG deficiency or as TBG excess (2, 5-8). Heterozygous females usually have TBG values intermediate to those of affected and unaffected males.

We recently described an unusual family with low serum thyroid hormone concentrations due to TBG deficiency (12). The disorder was recognized fortuitously during the investigation of the proband for short stature which proved to be due to Turner's syndrome (female phenotype with a single X chromosome). Studies revealed a unique TBG which was expressed in the proband and other members of the family (TBG-Gary), which had greatly reduced affinity for T₄ that was 100-fold lower than normal (Refetoff, S., unpublished), as well as decreased stability resulting in its rapid *in vivo* denaturation (12). As a consequence, specific RIAs detected a decrease in the concentration of the abnormal native protein (nTBG) and an increase of denatured TBG (dnTBG) in the sera of the affected subjects.

We now present the results of cloning and sequencing this variant gene which revealed a T→A transversion in the coding region resulting in the replacement of Ile-96 with an Asn. This replacement creates a new site

for N-linked glycosylation. As TBG-Gary appears to have additional carbohydrate, we believe that its presence is likely responsible for the altered properties of this protein, probably through changes in the conformation of the molecule.

RESULTS AND DISCUSSION

A complete pedigree of living members of this family with their respective nTBG and dnTBG levels in serum is shown on Fig. 1. The nTBG concentrations in the two hemizygous affected subjects [the proband (III-1) and her father (II-2)] are 1.5% the mean normal level, while those of dnTBG are approximately 10-fold above the normal mean. Two heterozygous subjects [paternal grandmother (I-1) and sister (III-2)] have nTBG and dnTBG values intermediate between those of hemizygous-affected and unaffected subjects. Thus, the inheritance of TBG-Gary is clearly X-linked, as expected from the recent demonstration of a single TBG gene copy located on the X chromosome (13).

The 4.5-kilobase pair (kbp) TBG gene is contained within a 14 kbp *EcoRI* fragment and is composed of 4 protein coding exons (Fig. 2). The gene of the affected father (II-2, see Fig. 1) of the proband was isolated, and the sequences of these 4 exons were compared to those of a normal human liver TBG cDNA clone and a genomic TBG clone from a human X chromosome library (14) as well as 3 genomic clones from an individual with the common type TBG (Mori, Y., and S. Refetoff, unpublished). The only difference between these 6 sequences was a T→A transversion in the first protein coding exon of the TBG-Gary gene, 287 bp




Fig. 1. Pedigree of the Family Expressing TBG-Gary with Values of Native TBG (nTBG) and Denatured TBG (dnTBG)

Concentrations expressed in micrograms per dl are shown on the left of each symbol for nTBG and, boxed in on the top right of each symbol, for dnTBG. Mean normal values \pm 1 SD are 1530 ± 180 for nTBG and 6.1 ± 2.3 for dnTBG. Roman numerals indicate generations and numbers on the bottom right of each symbol identify individual subjects. Note that the proband (III-1, indicated by the arrow), has a single X chromosome (XO-Turner's syndrome).




Fig. 2. Structure of the TBG Gene and Sections of Sequencing Gels Showing the Mutation Site in TBG-Gary Compared to the Corresponding Sequence of the Common Type TBG (TBG-C)

In the diagram of the TBG gene, exons are represented by open boxes and intervening and flanking sequences by lines. Nucleotide 287, from the codon for the NH₂-terminus of the mature protein, is a T in TBG-C and A in TBG-Gary. Note that the resulting substitution of amino acid-(96) creates a potential N-linked glycosylation site (Asn-Cys-Ser). The amino acids at the intron splice sites are: intron-1, Ala-188 (G|CC); intron-2, Gly-279 (GG|A); and intron-3, Asn-328 (AAT|).

downstream of the starting point of the mature protein, resulting in the replacement of the normal Ile-96 codon (ATC) by Asn (AAC) (Fig. 2). This amino acid substitution, which was verified by sequencing both sense and antisense strands, creates a potential site of glycosylation (Asn-Cys-Ser). Moreover, the nucleotide substitution destroys the recognition site for the restriction enzyme *Sau3AI* (GATC→GAAC), which allowed us to relate the TBG abnormality in individual family members to the presence of the mutation.

This exon, from four key members of the family, was amplified using the polymerase catalyzed chain reaction and then was digested with *Sau3AI*. As shown in Fig. 3, the two affected hemizygous subjects (II-2 and III-1) differ from their normal unaffected relative (II-3) and an unrelated individual, expressing TBG-C, by having a 416 bp fragment, rather than one of 394 bp fragment, due to the inability of *Sau3AI* to cleave off a 24 bp fragment from the TBG-Gary gene. As expected, the heterozygous subject (III-2) has both 418 bp and 394 bp fragments. Thus, it seemed very likely that the TBG




Fig. 3. Detection of the TBG-Gary mutation by *Sau*3AI digestion of amplified DNA sequences

The strategy of analysis is shown diagrammatically on the upper portion of the figure. The coding sequences of the first exon (stippled area) is contained in the amplified 903 bp fragment having at each end sequences corresponding to the two primers (A and B, see *Materials and methods*). The positions of the *Sau*3AI sites (S) and the expected sizes of fragments generated after digestion of TBG-C and TBG-Gary alleles are indicated (bars and numbers). The mutation of TBG-Gary resulting in the loss of the recognition site for *Sau*3AI (S*) generates a 418 bp (bold bar) rather than the normal 394 bp fragment generated by TBG-C. The 24 bp and 14 bp fragments are too small for visualization on the gel.

Lanes 1 and 2, Cloned TBG-Gary gene, undigested and after digestion, respectively; ϕ X 174 and pBR 322, markers digested with *Hae*III and *Msp*I, respectively; TBG-C, an unrelated subject expressing TBG-C, III-1 and II-2, hemizygous subjects expressing TBG-Gary (see Fig. 1); III-2, heterozygous subject expressing both TBG-C and TBG-Gary (see Fig. 1); II-3, mother of III-1 and III-2, expressing TBG-C (see Fig. 1).

abnormality observed in this family is due to the synthesis of TBG^{Asn-96}.

To determine whether the new potential site of glycosylation was indeed glycosylated, we exploited the observation that isoelectric focusing (IEF) can be used to reveal microheterogeneity in serum TBG resulting from variation in sialic acid content; addition of sialic acid reduces the isoelectric point (pI) of the TBG heteromolecule (15). The uniform anodal shift of all TBG-Gary bands (Fig. 4) is consistent with the presence of additional sialic acid in all heteromolecules, suggesting that Asn-96 of TBG-Gary is likely glycosylated.

Since no amino acid replacements other than the substitution of Asn for Ile at position 96 were found in TBG-Gary, it is likely that the abnormal properties of this protein are the consequence of this mutation. Although the Ile for Asn change is relatively conservative,




Fig. 4. IEF Analysis of TBG-Gary

Serum samples from two unrelated individuals with the common type TBG (TBG-C), from a subject with TBG-Gary (II-2, see Fig. 1) and a subject with complete TBG deficiency (aTBGnemic) were incubated with [¹²⁵I]T₄ then submitted to IEF and radioautography. The four distinct bands with pI values ranging from 4.28 to 4.48 represent the normal microheterogeneous forms of TBG-C, each with decreasing sialic acid content. All four bands of TBG-Gary are shifted anodally (arrows) in accordance with an increased sialic acid content. No [¹²⁵I]T₄ localized to the TBG zone in the serum from the aTBGnemic subject. Note that the wide band of [¹²⁵I] activity cathodal to pH 4.5 represents [¹²⁵I]T₄ bound to secondary binding sites in prealbumin and albumin due to either the reduced T₄-binding affinity of TBG-Gary or absence of TBG in the aTBGnemic serum.

we cannot exclude a direct effect of this amino acid substitution on T₄ binding and TBG stability. We believe that it is more likely that the properties of TBG-Gary are due to the presence of the additional carbohydrate, possibly by altering the secondary or tertiary structure of the protein. This interpretation is supported by our previous observation that while glycosylation is required for TBG to assume its tertiary structure before secretion, the complete removal of carbohydrates from the mature secreted protein does not alter its biological or immunological properties (16, 17).

Since carbohydrate moieties are often required for the proteolytic or conformational stability of the protein component of glycoproteins (18), we searched for other examples of naturally occurring mutations resulting in a loss or gain of Asn. Of the seven such mutations reported in man (19–24), none resulted in the elimination or creation of the canonical recognition signal, Asn-Xaa-Ser/Thr, for N-linked glycosylation (25). One of these mutations, a substitution of Ser-406 for Asn in the immunoglobulin μ heavy chain, created the sequence Thr-Phe-Asn which surprisingly appears to be more highly glycosylated (22). The molecule is defective in initiating complement-dependent cytotoxicity. Santos-Aguado *et al.* (26) studied the functional role of carbohydrates in the α -chain of the major histocompatibility complex class I antigen by site-directed mutagenesis. The elimination of the unique glycosylation site on Asn-86, by its substitution with either Gln or Asp, lowered

or abolished expression of the molecule on the surface of transfected cells but retained most antigenic determinants. The functional defect of the molecule resulting from these mutations was attributed to conformational changes of the α -chain and its interaction with the β_2 -microglobulin.

We believe that this may be the first description of a natural mutation that results in the synthesis and secretion of an apparently abnormally glycosylated protein having altered biological properties. Finally, we would also like to propose changing the eponym, TBG-Gary, to TBG^{C^{Asn-96}} which better describes this first variant TBG to be characterized in molecular terms.

MATERIALS AND METHODS

Subjects and TBG Analyses

Blood was obtained from members of the family (see Fig. 1) for the identification of the variant TBG in their serum and for the isolation of DNA from white blood cells. Native TBG and dnTBG concentrations were measured by specific RIAs with the lowest level of detectability being 2 μ g/dl (27). IEF analysis of TBG was carried out as previously described (26) using a horizontal slab gel containing 5% acrylamide and 6.7% ampholines, covering a pH range of 4.2 to 4.9. Five microliters of sera from two subjects having normal concentrations of the common type TBG (TBG-C) and 32 μ l sera from two unrelated individuals expressing the variant TBG in low concentrations (TBG-Gary) or having complete TBG deficiency (aTBGnemic), were equilibrated, at room temperature, with 10 nCi [¹²⁵I]T₄ (SA, 1250 μ Ci/ μ g, New England Nuclear, Boston, MA) and applied to the prefocused gel. After completion of the IEF run, the gel was dried and radioautographed on X-AR5 film (Eastman Kodak, Rochester, NY). Note that application to the gel of 32 μ l of the normal serum diluted 60-fold with serum from the aTBGnemic subject, to adjust the concentration of TBG-C to that in serum of subjects with TBG-Gary, did not alter its IEF mobility.

Cloning and Sequencing

DNA, purified from white blood cells by the method of Madisen *et al.* (29), was digested with *Eco*RI, as directed by the manufacturer (Bethesda Research Laboratories, Gaithersburg, MD). Fragments of 10–20 kbp, which are enriched for the TBG gene, were isolated by electrophoresis in a low melting agarose gel (30) and ligated into *Eco*RI arms of λ EMBL-4. After packaging and infection of *Escherichia coli* strain LE 392, clones containing the TBG gene were identified by hybridization with the insert from human liver cDNA clone (λ C_{TBG-8}, 14) labeled with [³²P]deoxycytidine triphosphate by nick translation kit (Amersham, Arlington Heights, IL) according to the instructions of the manufacturer. Appropriate restriction fragments were subcloned into M13 mp18 or mp19 and sequenced by the dideoxy chain termination method (31).

DNA Amplification, Restriction Endonuclease Digestion, and Analysis by Electrophoresis

The DNA segment of the entire sequence of the first coding exon containing the mutation site was amplified using the polymerase catalyzed chain reaction (32, 33(B)). Oligonucleotides (20mers), 5'-CCCTGATGAGCACATCATCA-3' corresponding to the 5'-intron sense sequence (B) and 5'-CAGTGGAGCAGATCACTGTG-3' corresponding to 3'-intron antisense sequence (A) served as primers (Fig. 3). The pre-

dicted size of the amplified segments of genomic DNA from members of the family was verified by electrophoresis in 2.0% NuSieve GTG agarose gel (FMC BioProducts, Rockland, ME) and visualized with UV light after staining with ethidium bromide. Amplified DNA segments were digested with *Sau*3AI (Bethesda Research Laboratories, Gaithersburg, MD), and fragments were resolved by electrophoresis in 2.0% NuSieve agarose gel as previously described (33).

Acknowledgments

We wish to thank Dr. Stephen Burstein for identification of the propositus, the family for their cooperation, Dr. Junta Takamatsu for performing the isoelectric focusing, and Drs. L. Bartalena, P. Ceccarelli, A. L. Horwitz, T. N. Pullman, H. Seo, D. F. Steiner, G. Vassart, and R. Weiss for their helpful suggestions during the preparation of the manuscript.

Received September 30, 1988. Revised version received December 7, 1988. Accepted December 9, 1988.

Address requests for reprints to: Dr. Samuel Refetoff, Box 138, University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637.

This work was supported in part by USPHS Grant DK-15,070. Presented in part at the 62nd Annual Meeting of The American Thyroid Association, Washington, DC, September 17, 1987.

* Present address: Departments of Medicine and Pharmacology, University of Arizona, Tucson, Arizona 85719. † Present address: The Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.

REFERENCES

1. Robbins J, Bartalena L 1986 Plasma transport of thyroid hormones. In: Hennemann G (ed) *Thyroid Hormone Metabolism*. Marcel Dekker, New York, pp 3–38
2. Refetoff S 1979 Thyroid hormone transport. In DeGroot LJ (ed) *Endocrinology*, Grune & Stratton, New York, pp 347–356
3. Bartalena L, Robbins J 1984 Effect of tunicamycin and monensin on secretion of thyroxine-binding globulin by cultured human hepatoma (Hep G2) cells. *J Biol Chem* 259:13610–13614
4. Murata Y, Sarne DH, Horwitz AL, Lecocq R, Aden DP, Knowles BB, Refetoff S 1985 Characterization of thyroxine-binding globulin secreted by human hepatoma cell line. *J Clin Endocrinol Metab* 60:472–478
5. Refetoff S, Robin NI, Alper CA 1972 Study of four new kindred with inherited thyroxine binding globulin (TBG) abnormalities: possible mutations of a single gene locus. *J Clin Invest* 51:848–867
6. Burr WA, Ramsden DB, Hoffenberg R, 1980 Hereditary abnormalities of thyroxine-binding globulin concentration; a study of 19 kindreds with inherited increase or decrease of thyroxine-binding globulin. *Q J Med* 49:295–313
7. Refetoff S, Murata Y 1985 X-Chromosome-linked inheritance of the thyroxine-binding globulin in Australian aborigines. *J Clin Endocrinol Metab* 60:356–360
8. Refetoff S, Selenkow HA 1968 Familial thyroxine-binding globulin deficiency in a patient with Turner's syndrome (XO). *N Engl J Med* 278:1081–1087
9. Leahy BC, Davies D, Laing I, Walton L 1984 High serum thyroxine-binding globulin: an important cause for hyperthyroxinemia. *Postgrad Med J* 60:324–327
10. Griffiths KD, Virdi NK, Green A, Rayner PHW 1985 Neonatal screening for congenital hypothyroidism by measurement of plasma thyroxine and thyroid stimulating hormone concentrations. *Br Med J* 291:117–120

11. Jenkins MB, Steffes MW 1987 Congenital thyroxine binding globulin deficiency: incidence and inheritance. *Hum Genet* 77:80–84
12. Murata Y, Takamatsu J, Refetoff S 1986 Inherited abnormality of thyroxine-binding globulin with no demonstrable activity and high serum levels of denatured thyroxine-binding globulin. *N Engl J Med* 314:694–699
13. Trent JM, Flink IL, Morkin E, Van Tuinen P-, Ledbetter DH 1987 Localization of the human thyroxine-binding globulin gene to the long arm of the X chromosome (Xq21-22). *Am J Hum Genet* 41:428–435
14. Flink IL, Bailey TJ, Gustafson TA, Markham BE, Morkin E 1986 Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: close homology to the serine antiproteases. *Proc Natl Acad Sci USA* 83:7708–7712
15. Ain KB, Mori Y, Refetoff S 1987 Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. *J Clin Endocrinol Metab* 65:689–696
16. Murata Y, Magner JA, Refetoff S 1986 The role of glycosylation in the molecular conformation and secretion of thyroxine-binding globulin. *J Clin Endocrinol Metab* 118:1614–1621
17. Cheng S-Y, Morrone S, Robbins J 1979 Effect of glycosylation on the binding and immunoreactivity of human thyroxine-binding globulin. *J Biol Chem* 254:8830–8835
18. Olden K, Parent JB, White SL 1982 Carbohydrate moieties of glycoproteins: a re-evaluation of their function. *Biochim Biophys Acta* 650:209–232
19. Zeng Y-T, Headlee ME, Henson J, Lam H, Wilson JB, Huisman THJ 1982 Identification of hemoglobin G-Philadelphia (α 68 Asn→Lys) and hemoglobin Matsue-oki (α 75 Asp→Asn) in a Black infant. *Biochim Biophys Acta* 707:206–212
20. Sugihara J, Yokota E, Kagimoto M, Naito Y, Imamura T 1984 Hemoglobin G Waimanalo: α 64 (E13) aspartic acid→asparagine observed in a Japanese family. *Hemoglobin* 8:79–82
21. Wilson JM, Kelley WN 1983 Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in a patient with Lesch-Nyhan syndrome. *J Clin Invest* 71:1331–1335
22. Shulman MJ, Pennell N, Collins C, Hozumi N 1986 Activation of complement by immunoglobulin M is impaired by the substitution serine-406→asparagine in the immunoglobulin μ heavy chain. *Proc Natl Acad Sci USA* 83:7678–7682
23. Amor M, Parker KL, Globerman H, New MI, White PC 1988 Mutation in the *CYP21B* gene (Ile-172→Asn) causes steroid 21-hydroxylase deficiency. *Proc Natl Acad Sci USA* 85:1600–1604
24. Huss K, Putnam FW, Takahashi N, Takahashi Y, Weaver GA, Peters Jr T 1988 Albumin Cooperstown: a serum albumin variant with the same (313 Lys→Asn) mutation found in albumins in Italy and New Zealand. *Clin Chem* 34:183–187
25. Hubbard SC, Ivatt RJ 1981 Synthesis and processing of asparagine-linked oligosaccharides. *Annu Rev Biochem* 50:555–583
26. Santos-Aguado J, Biro PA, Fuhrmann U, Strominger JL, Barbosa JA 1987 Amino acid sequences in the α 1 domain and not glycosylation are important in HLA-A2/ β 2-microglobulin association and cell surface expression. *Mol Cell Biol* 7:982–990
27. Refetoff S, Murata Y, Vassart G, Chandramouli V, Marshall JS 1984 Radioimmunoassays specific for the tertiary and primary structures of thyroxine-binding globulin (TBG): measurement of denatured TBG in serum. *J Clin Endocrinol Metab* 59:269–277
28. Takamatsu J, Ando M, Weinberg M, Refetoff S 1986 Isoelectric focusing variant thyroxine-binding globulin in American blacks: increased heat lability and reduced serum concentration. *J Clin Endocrinol Metab* 63:80–87
29. Madisen L, Hoar DI, Holroyd CD, Crisp M, Hodes ME 1987 DNA banking: the effect of storage in blood and isolated DNA on the integrity of DNA. *Am J Med Genet* 27:379–390
30. Wieslander L 1979 A simple method to recover intact high molecular weight RNA and DNA after electrophoretic separation in low gelling temperature agarose gels. *Anal Biochem* 98:305–309
31. Sanger F, Nicklen S, Coulson AR 1977 DNA sequencing with chain-terminating inhibitor. *Proc Natl Acad Sci USA* 74:5463–5467
32. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA 1988 Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. *Science* 239:481–491
33. Takeda K, Mori Y, Sobieszczek S, Dick M, Watson F, Flink IL, Seino S, Bell GI, Refetoff S, Sequence of the variant thyroxine-binding globulin of Australian Aborigines: only one of two amino acid replacements is responsible for its altered properties. *J Clin Invest*, in press

